Standard versus accelerated riboflavin/ultraviolet corneal cross-linking: Resistance against enzymatic digestion

Aldahlawi, Nada, Hayes, Sally ORCID: https://orcid.org/0000-0001-8550-0108, OBrart, David and Meek, Keith Michael Andrew ORCID: https://orcid.org/0000-0002-9948-7538 2015. Standard versus accelerated riboflavin/ultraviolet corneal cross-linking: Resistance against enzymatic digestion. Journal of Cataract and Refractive Surgery 41 (9) , pp. 1989-1996. 10.1016/j.jcrs.2015.10.004

Preview

PDF Available under License Creative Commons Attribution. Download (550kB) | Preview

Abstract

Purpose To examine the effect of standard and accelerated corneal collagen crosslinking (CXL) on corneal enzymatic resistance. Setting School of Optometry and Vision Sciences, Cardiff University, Cardiff, United Kingdom. Design Experimental study. Methods Sixty-six enucleated porcine eyes (with corneal epithelium removed) were assigned to 6 groups. Group 1 remained untreated, group 2 received dextran eyedrops, and groups 3 to 6 received riboflavin/dextran eyedrops. Group 4 had standard CXL (3 mW/cm2 ultraviolet-A for 30 minutes), whereas groups 5 and 6 received accelerated CXL (9 mW/cm2 for 10 minutes and 18 mW/cm2 for 5 minutes, respectively). Trephined central 8.0 mm buttons from each cornea underwent pepsin digestion. Corneal diameter was measured daily, and the dry weight of 5 samples from each group was recorded after 12 days of digestion. Results All CXL groups (4 to 6) took longer to digest and had a greater dry weight at 12 days (P < .0001) than the nonirradiated groups (1 to 3) (P < .0001). The time taken for complete digestion to occur did not differ between the standard and accelerated CXL groups, but the dry weights at 12 days showed significant differences between treatments: standard CXL 3 mW > accelerated CXL 9 mW > accelerated CXL 18 mW (P < .0001). Conclusions Standard and accelerated CXL both increased corneal enzymatic resistance; however, the amount of CXL might be less when accelerated CXL is used. The precise amount of CXL needed to prevent disease progression is not yet known

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Optometry and Vision Sciences
Subjects:	R Medicine > RE Ophthalmology
Publisher:	Elsevier
ISSN:	0886-3350
Funders:	MRC
Date of First Compliant Deposit:	30 March 2016
Date of Acceptance:	27 April 2015
Last Modified:	05 May 2023 23:33
URI:	https://orca.cardiff.ac.uk/id/eprint/77892

Citation Data

Cited 37 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item